1
|
Paparella AS, Brew I, Hong HA, Ferriera W, Cutting S, Lamiable-Oulaidi F, Popadynec M, Tyler PC, Schramm VL. Isofagomine Inhibits Multiple TcdB Variants and Protects Mice from Clostridioides difficile-Induced Mortality. ACS Infect Dis 2024; 10:928-937. [PMID: 38334357 DOI: 10.1021/acsinfecdis.3c00507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/10/2024]
Abstract
Clostridioides difficile causes life-threatening diarrhea and is one of the leading causes of nosocomial infections. During infection, C. difficile releases two gut-damaging toxins, TcdA and TcdB, which are the primary determinants of disease pathogenesis and are important therapeutic targets. Once in the cytosol of mammalian cells, TcdA and TcdB use UDP-glucose to glucosylate host Rho GTPases, which leads to cytoskeletal changes that result in a loss of intestinal integrity. Isofagomine inhibits TcdA and TcdB as a mimic of the glucocation transition state of the glucosyltransferase reaction. However, sequence variants of TcdA and TcdB across the clades of infective C. difficile continue to be identified, and therefore, evaluation of isofagomine inhibition against multiple toxin variants is required. Here, we show that isofagomine inhibits the glucosyltransferase domain of multiple TcdB variants and protects TcdB-induced cell rounding of the most common full-length toxin variants. Furthermore, we demonstrate that isofagomine protects against C. difficile-induced mortality in two murine models of C. difficile infection. Isofagomine treatment of mouse C. difficile infection also permitted the recovery of the gastrointestinal microbiota, an important barrier to preventing recurring C. difficile infection. The broad specificity of isofagomine supports its potential as a prophylactic to protect against C. difficile-induced morbidity and mortality.
Collapse
Affiliation(s)
- Ashleigh S Paparella
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States
| | - Isabella Brew
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States
| | - Huynh A Hong
- SporeGen Ltd., The London BioScience Innovation Centre, London NW1 0NH, U.K
| | - William Ferriera
- SporeGen Ltd., The London BioScience Innovation Centre, London NW1 0NH, U.K
| | - Simon Cutting
- SporeGen Ltd., The London BioScience Innovation Centre, London NW1 0NH, U.K
| | - Farah Lamiable-Oulaidi
- The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand
| | - Michael Popadynec
- The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand
| | - Peter C Tyler
- The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt 5010, New Zealand
| | - Vern L Schramm
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States
| |
Collapse
|
2
|
Paparella AS, Brew I, Hong HA, Ferriera W, Cutting S, Lamiable-Oulaidi F, Popadynec M, Tyler PC, Schramm VL. Isofagomine inhibits multiple TcdB variants and protects mice from Clostridioides difficile induced mortality. bioRxiv 2023:2023.09.19.558375. [PMID: 37781587 PMCID: PMC10541099 DOI: 10.1101/2023.09.19.558375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/03/2023]
Abstract
Clostridioides difficile causes life-threatening diarrhea and is the leading cause of healthcare associated bacterial infections in the United States. During infection, C. difficile releases the gut-damaging toxins, TcdA and TcdB, the primary determinants of disease pathogenesis and are therefore therapeutic targets. TcdA and TcdB contain a glycosyltransferase domain that uses UDP-glucose to glycosylate host Rho GTPases, causing cytoskeletal changes that result in a loss of intestinal integrity. Isofagomine inhibits TcdA and TcdB as a mimic of the oxocarbenium ion transition state of the glycosyltransferase reaction. However, sequence variants of TcdA and TcdB across the clades of infective C. difficile continue to be identified and therefore, evaluation of isofagomine inhibition against multiple toxin variants are required. Here we show that Isofagomine inhibits the glycosyltransferase activity of multiple TcdB variants and also protects TcdB toxin-induced cell rounding of the most common full-length toxin variants. Further, isofagomine protects against C. difficile induced mortality in two murine models of C. difficile infection. Isofagomine treatment of mouse C. difficile infection permitted recovery of the gastrointestinal microbiota, an important barrier to prevent recurring C. difficile infection. The broad specificity of isofagomine supports its potential as a prophylactic to protect against C. difficile induced morbidity and mortality.
Collapse
Affiliation(s)
- Ashleigh S. Paparella
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Isabella Brew
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
| | - Huynh A. Hong
- SporeGen Ltd, The London BioScience Innovation Centre, London, United Kingdom
| | - William Ferriera
- SporeGen Ltd, The London BioScience Innovation Centre, London, United Kingdom
| | - Simon Cutting
- SporeGen Ltd, The London BioScience Innovation Centre, London, United Kingdom
| | - Farah Lamiable-Oulaidi
- The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand
| | - Michael Popadynec
- The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand
| | - Peter C. Tyler
- The Ferrier Research Institute, Victoria University of Wellington, Lower Hutt, New Zealand
| | - Vern L. Schramm
- Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA
| |
Collapse
|
3
|
Popadynec M, Baradaran-Heravi A, Alford B, Cameron SA, Clinch K, Mason JM, Rendle PM, Zubkova OV, Gan Z, Liu H, Rebollo O, Whitfield DM, Yan F, Roberge M, Powell DA. Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets. ACS Med Chem Lett 2021; 12:1486-1492. [PMID: 34531957 DOI: 10.1021/acsmedchemlett.1c00349] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Accepted: 08/04/2021] [Indexed: 11/29/2022] Open
Abstract
A significant proportion of genetic disease cases arise from truncation of proteins caused by premature termination codons. In eukaryotic cells some aminoglycosides cause readthrough of premature termination codons during protein translation. Inducing readthrough of these codons can potentially be of therapeutic value in the treatment of numerous genetic diseases. A significant drawback to the repeated use of aminoglycosides as treatments is the lack of balance between their readthrough efficacy and toxicity. The synthesis and biological testing of designer aminoglycoside compounds is documented herein. We disclose the implementation of a strategy to reduce cellular toxicity and maintain readthrough activity of a library of compounds by modification of the overall cationic charge of the aminoglycoside scaffold through ring I modifications.
Collapse
Affiliation(s)
- Michael Popadynec
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand
| | - Alireza Baradaran-Heravi
- Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada
| | - Benjamin Alford
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand
| | - Scott A. Cameron
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand
| | - Keith Clinch
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand
| | - Jennifer M. Mason
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand
| | - Phillip M. Rendle
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand
| | - Olga V. Zubkova
- Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand
| | - Zhonghong Gan
- Sussex Research Laboratories, Inc., 100 Sussex Drive, Suite 1120B, Ottawa, Ontario K1A 0R6, Canada
| | - Hui Liu
- Sussex Research Laboratories, Inc., 100 Sussex Drive, Suite 1120B, Ottawa, Ontario K1A 0R6, Canada
| | - Oscar Rebollo
- Sussex Research Laboratories, Inc., 100 Sussex Drive, Suite 1120B, Ottawa, Ontario K1A 0R6, Canada
| | - Dennis M. Whitfield
- Sussex Research Laboratories, Inc., 100 Sussex Drive, Suite 1120B, Ottawa, Ontario K1A 0R6, Canada
| | - Fengyang Yan
- Sussex Research Laboratories, Inc., 100 Sussex Drive, Suite 1120B, Ottawa, Ontario K1A 0R6, Canada
| | - Michel Roberge
- Department of Biochemistry and Molecular Biology, University of British Columbia, 2350 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada
| | - David A. Powell
- Inception Sciences Canada, 210-887 Great Northern Way, Vancouver, British Columbia, V5T 4T5, Canada
| |
Collapse
|
4
|
Graham MA, Askey H, Campbell AD, Chan L, Cooper KG, Cui Z, Dalgleish A, Dave D, Ensor G, Galan Espinosa MR, Hamilton P, Heffernan C, Jackson LV, Jing D, Jones MF, Liu P, Mulholland KR, Pervez M, Popadynec M, Randles E, Tomasi S, Wang S. Development and Scale-Up of an Improved Manufacturing Route to the ATR Inhibitor Ceralasertib. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00482] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Mark A. Graham
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Hannah Askey
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Andrew D. Campbell
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Lai Chan
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Katie G. Cooper
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Zhaoshan Cui
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| | - Andrew Dalgleish
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - David Dave
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Gareth Ensor
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Maria Rita Galan Espinosa
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Peter Hamilton
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Claire Heffernan
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Lucinda V. Jackson
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Dajiang Jing
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| | - Martin F. Jones
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Pengpeng Liu
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| | - Keith R. Mulholland
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Mohammed Pervez
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Michael Popadynec
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Emma Randles
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Simone Tomasi
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield SK10 2NA, U.K
| | - Shenghua Wang
- Asymchem Laboratories (Tianjin) Co. Ltd., TEDA, Tianjin 300457, P. R. China
| |
Collapse
|
5
|
Popadynec M, Gibbard H, Clark JS. Bidirectional Synthesis of the IJK Fragment of Ciguatoxin CTX3C by Sequential Double Ring-Closing Metathesis and Tsuji-Trost Allylation. Org Lett 2020; 22:3734-3738. [PMID: 32306737 PMCID: PMC7304930 DOI: 10.1021/acs.orglett.0c01238] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Abstract
![]()
A novel four-step bidirectional strategy
has been used to synthesize
the IJK fragment of the marine polyether natural product CTX3C from
a simple monocyclic precursor in a concise and efficient manner. The
four-step bidirectional sequence involves ring-closing metathesis,
alcohol oxidation, enol carbonate formation, and palladium-mediated
Tsuji–Trost allylation.
Collapse
Affiliation(s)
- Michael Popadynec
- School of Chemistry, Joseph Black Building, University of Glasgow, University Avenue, Glasgow, G12 8QQ, United Kingdom
| | - Helen Gibbard
- School of Chemistry, Joseph Black Building, University of Glasgow, University Avenue, Glasgow, G12 8QQ, United Kingdom
| | - J Stephen Clark
- School of Chemistry, Joseph Black Building, University of Glasgow, University Avenue, Glasgow, G12 8QQ, United Kingdom
| |
Collapse
|